JP2018510132A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510132A5 JP2018510132A5 JP2017540830A JP2017540830A JP2018510132A5 JP 2018510132 A5 JP2018510132 A5 JP 2018510132A5 JP 2017540830 A JP2017540830 A JP 2017540830A JP 2017540830 A JP2017540830 A JP 2017540830A JP 2018510132 A5 JP2018510132 A5 JP 2018510132A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain consists
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102100019461 CD28 Human genes 0.000 claims 6
- 101700033362 CD28 Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108090001123 antibodies Proteins 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 4
- 102100019451 CD80 Human genes 0.000 claims 3
- 101700080477 CD80 Proteins 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- 108010061171 Abatacept Proteins 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100003729 CD40LG Human genes 0.000 claims 1
- 229950001109 Galiximab Drugs 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000037240 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 108010012206 galiximab Proteins 0.000 claims 1
Claims (5)
- ＣＤ４０Ｌに結合する単離抗体の有効成分を含む筋委縮性側索硬化症の治療のための医薬組成物であって、単離抗体が軽鎖および重鎖配列を含み、ここで
１）軽鎖が配列番号７のアミノ酸配列からなり、かつ重鎖が配列番号９のアミノ酸配列からなり；
２）軽鎖が配列番号７のアミノ酸配列からなり、かつ重鎖が配列番号１３のアミノ酸配列からなり；
３）軽鎖が配列番号１１のアミノ酸配列からなり、かつ重鎖が配列番号９のアミノ酸配列からなり；または
４）軽鎖が配列番号１１のアミノ酸配列からなり、かつ重鎖が配列番号１３のアミノ酸配列からなり；
かつ前記医薬組成物が生理的に許容可能な担体をさらに含む、医薬組成物。 - 前記抗体が、別の治療薬と組み合わせて投与される、請求項１に記載の医薬組成物。
- 前記抗体が、ＣＤ２８とＣＤ８６の間またはＣＤ２８とＣＤ８０の間の相互作用を遮断する化合物と組合せて投与される、請求項２に記載の医薬組成物。
- ＣＤ２８とＣＤ８６の間またはＣＤ２８とＣＤ８０の間の相互作用を遮断する前記化合物が、ＣＴＬＡ４−Ｉｇ融合タンパク質である、請求項３に記載の医薬組成物。
- ＣＤ２８とＣＤ８６の間またはＣＤ２８とＣＤ８０の間の相互作用を遮断する前記化合物が、アバタセプトまたはベラタセプトまたはガリキシマブである、請求項３に記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562111261P | 2015-02-03 | 2015-02-03 | |
| US62/111,261 | 2015-02-03 | ||
| PCT/US2016/016165 WO2016126702A1 (en) | 2015-02-03 | 2016-02-02 | Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191310A Division JP2021054826A (ja) | 2015-02-03 | 2020-11-18 | Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510132A JP2018510132A (ja) | 2018-04-12 |
| JP2018510132A5 true JP2018510132A5 (ja) | 2019-03-14 |
| JP6797810B2 JP6797810B2 (ja) | 2020-12-09 |
Family
ID=56564599
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540830A Active JP6797810B2 (ja) | 2015-02-03 | 2016-02-02 | Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法 |
| JP2020191310A Pending JP2021054826A (ja) | 2015-02-03 | 2020-11-18 | Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法 |
| JP2022199466A Pending JP2023036717A (ja) | 2015-02-03 | 2022-12-14 | Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020191310A Pending JP2021054826A (ja) | 2015-02-03 | 2020-11-18 | Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法 |
| JP2022199466A Pending JP2023036717A (ja) | 2015-02-03 | 2022-12-14 | Ｃｄ４０ｌ関連疾患または障害を治療するための抗ｃｄ４０ｌ抗体及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10106618B2 (ja) |
| EP (2) | EP3253412B1 (ja) |
| JP (3) | JP6797810B2 (ja) |
| KR (1) | KR20170108024A (ja) |
| CN (2) | CN114195895A (ja) |
| AU (2) | AU2016215505B8 (ja) |
| CA (1) | CA2974135A1 (ja) |
| DK (1) | DK3253412T3 (ja) |
| GB (1) | GB2552429A (ja) |
| IL (2) | IL253571B (ja) |
| MA (1) | MA41459A (ja) |
| MX (2) | MX2017009694A (ja) |
| RU (1) | RU2727646C2 (ja) |
| SG (2) | SG10201912752QA (ja) |
| WO (1) | WO2016126702A1 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3556774T (pt) | 2011-03-11 | 2024-02-29 | Beth Israel Deaconess Medical Ct Inc | Anticorpos anti-cd40 e suas utilizações |
| MA41459A (fr) * | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| MX2018002708A (es) | 2015-09-04 | 2018-08-01 | Primatope Therapeutics Inc | Anticuerpos anti-cd40 humanizados y usos de los mismos. |
| KR20200010294A (ko) * | 2017-05-24 | 2020-01-30 | 에이엘에스 테라피 디벨럽먼트 인스티튜트 | 치료용 항-cd40 리간드 항체 |
| US20220380478A1 (en) * | 2019-07-01 | 2022-12-01 | Tonix Pharma Holdings Limited | Anti-cd154 antibodies and uses thereof |
| US20220259278A1 (en) * | 2019-07-08 | 2022-08-18 | Progen Co., Ltd. | Novel fusion protein and use of same |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| EP4274587A1 (en) * | 2021-01-06 | 2023-11-15 | Tonix Pharma Limited | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
| KR20230152032A (ko) | 2021-02-03 | 2023-11-02 | 모차르트 쎄라퓨틱스 인코포레이티드 | 결합제 및 이를 사용하는 방법 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| CN114149508B (zh) * | 2021-11-25 | 2023-04-28 | 苏州普乐康医药科技有限公司 | 一种结合cd40l的融合蛋白及其应用 |
| KR20230108156A (ko) * | 2022-01-10 | 2023-07-18 | 주식회사 금호에이치티 | Cd40l에 특이적으로 결합하는 항체 및 그의 용도 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5961974A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US7070777B1 (en) | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
| CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
| JP2991499B2 (ja) | 1993-09-02 | 1999-12-20 | トラスティーズ・オブ・ダートマス・カレッジ | 抗ｇｐ３９抗体およびその用途 |
| US5833987A (en) | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
| HUP0000833A3 (en) | 1997-01-10 | 2001-09-28 | Biogen Idec Ma Inc Cambridge | Treatment of lupus nephritis with anti-cd40l compounds |
| AU735592B2 (en) | 1997-05-17 | 2001-07-12 | Biogen Idec Ma Inc. | Use of a CD40:CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection |
| WO1999051258A1 (en) | 1998-04-03 | 1999-10-14 | Trustees Of Dartmouth College | USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| IL149500A0 (en) | 1999-11-08 | 2002-11-10 | Idec Pharma Corp | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| JP2003524644A (ja) | 2000-02-01 | 2003-08-19 | タノックス インコーポレイテッド | Ｃｄ４０−結合性ａｐｃ−活性化分子 |
| GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| WO2001083755A2 (en) | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| RU2270691C2 (ru) * | 2000-05-12 | 2006-02-27 | Бет Израел Диконесс Медикал Сентер, Инк. | Композиции и способы достижения иммунной супрессии |
| IL153764A0 (en) | 2000-07-12 | 2003-07-06 | Idec Pharma Corp | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| AU8867501A (en) | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| EP1399435A2 (en) | 2000-09-01 | 2004-03-24 | Biogen, Inc. | Pyridine derivatives useful as cd40:cd154 binding interruptors and use thereof to treat immunological complications |
| WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| US20040146949A1 (en) | 2002-10-25 | 2004-07-29 | Jun Tan | Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease |
| CA2528551A1 (en) | 2003-06-13 | 2005-01-13 | Biogen Idec Ma Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| JP2007527703A (ja) | 2003-07-08 | 2007-10-04 | ジェネスト アー／エス | 肺炎球菌表面付着因子Ａタンパク質（ＰｓａＡ）に関する結合メンバー |
| CA2533593A1 (en) | 2003-07-26 | 2005-02-10 | Biogen Idec Ma Inc. | Altered antibodies having improved antigen-binding affinity |
| AU2004266159A1 (en) * | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| US20170166655A1 (en) | 2004-03-26 | 2017-06-15 | Xencor, Inc. | Novel immunoglobulin variants |
| AU2005287406B2 (en) | 2004-07-26 | 2011-08-18 | Biogen Ma Inc. | Anti-CD154 antibodies |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2006138316A2 (en) | 2005-06-14 | 2006-12-28 | Biogen Idec Ma Inc. | Methods for delivering molecules to the central nervous system |
| ES2425571T3 (es) | 2005-11-17 | 2013-10-16 | Biogen Idec Ma Inc. | Ensayos de agregación plaquetaria |
| AR058567A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Formulaciones de proteinas estables |
| US7647438B1 (en) * | 2006-05-09 | 2010-01-12 | Integrated Device Technology, Inc. | Binary base address sorting method and device with shift vector |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| MX2009010120A (es) | 2007-03-22 | 2009-10-19 | Ucb Pharma Sa | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. |
| BRPI0811857A2 (pt) * | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
| GB0815788D0 (en) | 2008-08-29 | 2008-10-08 | Isis Innovation | Therapeutic antibodies |
| DK2367849T3 (en) * | 2008-12-05 | 2018-01-22 | Als Therapy Development Inst | METHOD OF TREATING NEURODEGENERATIVE DISEASES |
| US9044459B2 (en) | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| US20120100140A1 (en) | 2009-01-23 | 2012-04-26 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
| WO2012103218A1 (en) | 2011-01-25 | 2012-08-02 | University Of South Florida | A transgenic model of alzheimer's disease |
| SG193554A1 (en) | 2011-03-29 | 2013-11-29 | Roche Glycart Ag | Antibody fc variants |
| CA2832281C (en) | 2011-04-04 | 2019-11-05 | Trustees Of Dartmouth College | Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies |
| US9028826B2 (en) | 2011-04-04 | 2015-05-12 | The Trustees Of Dartmouth College | Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| MA35035B1 (fr) * | 2011-04-21 | 2014-04-03 | Bristol Myers Squibb Co | Anticorps polypeptidiques qui antagonisent les cd40 |
| JP2015527869A (ja) | 2011-08-26 | 2015-09-24 | メリマック ファーマシューティカルズ インコーポレーティッド | タンデムＦｃ二重特異性抗体 |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| PT2766395T (pt) * | 2011-10-13 | 2020-02-04 | Domantis Ltd | Polipéptidos de anticorpo que antagonizam cd40l |
| SG10201609447XA (en) | 2012-05-11 | 2017-01-27 | Medimmune Llc | Ctla-4 variants |
| EP2909303B1 (en) | 2012-10-18 | 2020-04-15 | Yongxin Zhang | Bioreactor system and methods for alternative cell culture between static and dynamic |
| EP3783017A1 (en) * | 2013-04-02 | 2021-02-24 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| US20170051059A1 (en) | 2014-03-19 | 2017-02-23 | Bristol-Myers Squibb Company | Methods of treating transplant rejection using a domain antibody directed against cd40 |
| MX2016013611A (es) | 2014-04-25 | 2017-02-02 | Bristol Myers Squibb Co | Uso del compuesto antigeno 4 del linfocito t toxico (ctla4) para lograr la remision libre de farmacos en sujetos con artritis reumatoide (ra) temprana. |
| US20170233485A1 (en) | 2014-08-18 | 2017-08-17 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| MA41459A (fr) * | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| KR20200010294A (ko) | 2017-05-24 | 2020-01-30 | 에이엘에스 테라피 디벨럽먼트 인스티튜트 | 치료용 항-cd40 리간드 항체 |
-
2016
- 2016-02-01 MA MA041459A patent/MA41459A/fr unknown
- 2016-02-02 SG SG10201912752QA patent/SG10201912752QA/en unknown
- 2016-02-02 MX MX2017009694A patent/MX2017009694A/es unknown
- 2016-02-02 JP JP2017540830A patent/JP6797810B2/ja active Active
- 2016-02-02 CN CN202111202841.7A patent/CN114195895A/zh active Pending
- 2016-02-02 AU AU2016215505A patent/AU2016215505B8/en active Active
- 2016-02-02 KR KR1020177021029A patent/KR20170108024A/ko not_active Application Discontinuation
- 2016-02-02 EP EP16747111.9A patent/EP3253412B1/en active Active
- 2016-02-02 EP EP22163613.7A patent/EP4071175A1/en active Pending
- 2016-02-02 GB GB1713871.0A patent/GB2552429A/en not_active Withdrawn
- 2016-02-02 RU RU2017126997A patent/RU2727646C2/ru active
- 2016-02-02 DK DK16747111.9T patent/DK3253412T3/da active
- 2016-02-02 CN CN201680008506.4A patent/CN108064168B/zh active Active
- 2016-02-02 SG SG11201706258WA patent/SG11201706258WA/en unknown
- 2016-02-02 WO PCT/US2016/016165 patent/WO2016126702A1/en active Application Filing
- 2016-02-02 CA CA2974135A patent/CA2974135A1/en active Pending
-
2017
- 2017-07-19 IL IL253571A patent/IL253571B/en unknown
- 2017-07-26 MX MX2022005655A patent/MX2022005655A/es unknown
- 2017-08-02 US US15/667,477 patent/US10106618B2/en active Active
-
2018
- 2018-09-07 US US16/125,317 patent/US10683356B2/en active Active
-
2020
- 2020-05-13 US US15/931,315 patent/US11014990B2/en active Active
- 2020-11-18 JP JP2020191310A patent/JP2021054826A/ja active Pending
-
2021
- 2021-05-17 US US17/322,486 patent/US11692040B2/en active Active
- 2021-11-03 IL IL287823A patent/IL287823A/en unknown
-
2022
- 2022-01-19 AU AU2022200323A patent/AU2022200323A1/en active Pending
- 2022-12-14 JP JP2022199466A patent/JP2023036717A/ja active Pending
-
2023
- 2023-06-26 US US18/341,202 patent/US20240043549A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510132A5 (ja) | ||
| JP2019500327A5 (ja) | ||
| HRP20210250T1 (hr) | Učinkovita i djelotvorna kontrola serumskog fosfata za optimalno stvaranje kostiju | |
| JP2012136541A5 (ja) | ||
| JP2020518599A5 (ja) | ||
| JP2019507180A5 (ja) | ||
| JP2018501197A5 (ja) | ||
| JP2017503014A5 (ja) | ||
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JP2011219478A5 (ja) | ||
| JP2010202664A5 (ja) | ||
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| AR082629A1 (es) | Anticuerpos anti-fap (proteina de activacion fibroblastica) y metodos de uso | |
| JP2016527286A5 (ja) | ||
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| JP2012102122A5 (ja) | ||
| JP2013520405A5 (ja) | ||
| JP2018505882A5 (ja) | ||
| NZ705848A (en) | Anti-cd38 antibodies | |
| JP2019510739A5 (ja) | ||
| JP2018507220A5 (ja) | ||
| WO2018067217A3 (en) | COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF |